Revolutionizing MS Treatment:
A New Era Begins
About Us
Our
Origin
Convelo Therapeutics launched from the research laboratories of Professors Paul Tesar, PhD, and Drew Adams, PhD, at Case Western Reserve University, establishing the foundation for our mission.
Our
Ethos
Driven by curiosity and transformative creativity, we are dedicated to developing therapies for those in need. Our mission extends beyond medicine, as we strive to create a healthier, brighter future for people living with multiple sclerosis.
Our
Journey
From lab neighbors to pioneers in neurodegeneration treatment, the founding of Convelo Therapeutics in 2016 marked the start of our mission: transforming cutting-edge lab research into real-world medical breakthroughs. Here’s our journey so far:
Strategic Approach
Our goal at Convelo Therapeutics is transformative: not merely to ease symptoms but to halt and reverse neurodegeneration in MS and related conditions, thereby changing lives.
Trailblazing
Drug Discovery Platform
Our proprietary stem-cell platform is at the forefront of drug discovery, enabling us to rapidly screen compounds and identify promising candidates for myelin regeneration.
Strategic Alliances and
Experienced Leadership
Under the guidance of biotech visionary Derrick Rossi and through partnerships with leading institutions, Convelo is dedicated to transforming scientific discoveries into life-altering treatments.
Investing in a
Promising Future
With robust financial backing and a comprehensive license agreement with Case Western Reserve University, we are well-positioned to advance our drug portfolio towards clinical trials.
Our Technology
Targeting the
Oligodendrocyte
Convelo’s cutting-edge platform targets the oligodendrocyte progenitor cell, accelerating the development of new oligodendrocytes and new myelin, with the goal of stabilizing and reversing clinical progression in multiple sclerosis.
Investing in a Promising Future
Our robust financial foundations and comprehensive worldwide license agreement with Case Western Reserve University position us to propel our promising drug pipeline towards clinical trials. Our approach, supported by compelling preclinical evidence, holds the promise of profoundly improving the lives of those with demyelinating conditions.
Join Our Vision
Join us at Convelo Therapeutics as we cultivate hope for a future where myelin regeneration is a life-altering reality. Together with our partners, investors, and dedicated team, we’re forging a path toward a future rich with hope and groundbreaking therapies.
